ライフサイエンスコーパス: HBOC

1 HBOC-201 consists of polymerized bovine hemoglobin and h

2 HBOC-related breast cancers accumulated significantly mo

3 HBOCs have several advantages over human blood, includin

4 missense variant, L1420F, was observed in 13 HBOC families (4.8%) but was not observed in any of the

5 and brain oxygen for the first 8 hrs; and 2) HBOC-201 could be an effective salvage therapy after sev

6 hase," pigs were resuscitated with HBOC-201 (HBOC) or Hextend (HEX) or were nonresuscitated (NON).

7 In 270 HBOC families previously screened for BRCA1 and BRCA2 mu

8 f potential significance were observed in 65 HBOC families, but not in healthy controls.

9 ta are absent in most of these syndromes, an HBOC diagnosis may be missed unless a careful family his

10 idered as BRCA1-like biomarkers for TNBC and HBOC syndrome.

11 ate the pulmonary vasoconstriction caused by HBOC.

12 for hereditary breast and/or ovarian cancer (HBOC) is rapidly evolving owing to the recent introducti

13 ome of hereditary breast and ovarian cancer (HBOC).

14 both [hereditary breast and ovarian cancer (HBOC)].

15 DBBF-Hb, a Hb-based oxygen carrier (HBOC) for which toxic side effects have been well docume

16 n acellular hemoglobin-based oxygen carrier (HBOC) Hemopure in a human model of NMP-L.

17 a potential hemoglobin-based oxygen carrier (HBOC) in in vivo animal studies.

18 cell-free, hemoglobin-based oxygen carrier (HBOC) is systemic vasoconstriction.

19 AAP) with a hemoglobin-based oxygen carrier (HBOC-201) offers a potentially effective therapy.

20 Hemoglobin-based oxygen carriers (HBOC) of several types scavenge nitric oxide from the va

21 including hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbons.

22 rtain hemoglobin (Hb)-based oxygen carriers (HBOCs) may alter Hb structure and function, as amino aci

23 Hemoglobin-based oxygen carriers (HBOCs) of bovine hemoglobin (Hb) or human Hb origin were

24 acellular hemoglobin-based oxygen carriers (HBOCs).

25 iable hemoglobin (Hb)-based oxygen carriers (HBOCs).

26 Combined HBOC and sildenafil infusion resulted in stable systemic

27 port the continued investigation of combined HBOC and PDE5 inhibitor treatment in circumstances in wh

28 treatment can be largely overcome by combing HBOC treatment with a PDE5 inhibitor (sildenafil).

29 e hemoglobin-based oxygen carrying compound (HBOC-201) was administered to enhance the patient's oxyg

30 , hemoglobin-based oxygen carrying compound [HBOC]-201, Biopure).

31 ividuals who were appropriate candidates for HBOC evaluation and who lacked BRCA1/2 mutations.

32 y be a new genetic marker of cancer risk for HBOC families without other known genetic abnormalities.

33 entative cohort, multigene panel testing for HBOC risk assessment yielded findings likely to change c

34 apable of distinguishing plasma samples from HBOC patients as BRCA1-mutated and BRCA1 non-mutated, su

35 , and managing patients at high risk for HBC/HBOC.

36 lutaraldehyde-polymerized bovine hemoglobin (HBOC) with a PDE5 inhibitor would counter the negative h

37 lutaraldehyde-polymerized bovine hemoglobin (HBOC), sildenafil (PDE5 inhibitor), and lactated Ringer'

38 lutaraldehyde-polymerized bovine hemoglobin (HBOC-201, 1.44 g/kg).

39 In comparison with hetastarch, HBOC-201 resuscitation of swine with HS increased surviv

40 ar size tetrameric species (i.e., 64 kDa) in HBOC solutions.

41 c enzymes were generally similar or lower in HBOC than HEX pigs, but creatine kinase-MB (but not crea

42 Together, our data indicate that, in HBOC-related breast cancers, the accumulation of genomic

43 that the KRAS-variant was present in 61% of HBOC patients without BRCA1 or BRCA2 mutations, previous

44 had no significant effect on the actions of HBOC-201.

45 The basis of HBOC toxicity is poorly understood, however, several mec

46 1) A single bolus of HBOC-201 at initial resuscitation rapidly restored cereb

47 ter the negative hemodynamic consequences of HBOC therapy alone, resulting in improved hemodynamics a

48 These negative consequences of HBOC treatment can be largely overcome by combing HBOC t

49 The effects of HBOC-201-resuscitation in HS should be corroborated in c

50 Two formulations of HBOC-201 (average MW = 250 kDa) were tested: one with <3

51 inistered before the intravenous infusion of HBOC can prevent systemic vasoconstriction without causi

52 ypertension caused by subsequent infusion of HBOC-201.

53 was to determine the metabolic signature of HBOC syndrome and TNBC patients and to evaluate the pote

54 Only a subset of HBOC family members are likely to request BRCA1 testing

55 useful in the detection and confirmation of HBOCs in test samples.

56 entification, detection, and confirmation of HBOCs of bovine Hb or human Hb origin.

57 entification, detection, and confirmation of HBOCs.

58 ation, quantification, and distinguishing of HBOCs from native hemoglobin in test samples is needed.

59 r autoxidation in evaluating the toxicity of HBOCs.

60 ize (i.e., 64 kDa) has a direct influence on HBOC-mediated vasoactivity and that other protective str

61 of either normal saline (control, n = 14) or HBOC-201 (n = 14) was administered.

62 istration of murine tetrameric hemoglobin or HBOC-201 and did not result in conversion of plasma hemo

63 on of either murine tetrameric hemoglobin or HBOC-201 induced prolonged systemic vasoconstriction in

64 LR) solution (n = 6) or SAAP with oxygenated HBOC-201 (n = 6) at a rate of 10 mL x kg(-1) x min(-1) u

65 SAAP with oxygenated HBOC-201 rapidly restored viable cardiovascular function

66 ional phase III trial of the Biopure product HBOC-201 (Hemopure) has been completed in orthopedic sur

67 ne-hour survival was five of six in the SAAP-HBOC group and none of six in the SAAP-LR group (p <.05,

68 In the SAAP-HBOC group, return of spontaneous circulation with a sus

69 reditary breast and ovarian cancer syndrome (HBOC) as well as their family members.

70 reditary breast and ovarian cancer syndrome (HBOC) is partly due to the presence of mutations in the

71 n hereditary breast/ovarian cancer syndrome (HBOC).

72 These findings demonstrate that HBOC can cause systemic vasoconstriction by scavenging N

73 We tested the hypothesis that HBOC-201 would improve cerebrovascular resuscitation in

74 The HBOC used in this study resulted in pulmonary and system

75 The HBOC-perfused livers extracted more oxygen than those pe

76 t additional property is the capacity of the HBOC either to generate nitric oxide (NO) or to preserve

77 ional and vasoactive characteristics of this HBOC.

78 tabolomic analysis of plasma samples from TN HBOC patients taking into account their BRCA1 genotype.

79 However, the addition of sildenafil to HBOC did not fully ameliorate the pulmonary vasoconstric

80 nhibitor treatment in circumstances in which HBOC therapy is being considered.

81 In contrast, with HBOC-201 at 30 mins (n = 14), systolic arterial pressure

82 al biliary changes occurred exclusively with HBOC.

83 pillary injury occurred more frequently with HBOC, but consistent patterns for urine output, blood ur

84 se-MB/creatine kinase ratio) was higher with HBOC in moderate controlled HS.

85 r with HBOC and HEX, but Po2 was higher with HBOC in severe uncontrolled HS.

86 Survival was significantly higher with HBOC than HEX only with severe uncontrolled HS (p = .002

87 aline phosphatase were generally higher with HBOC than HEX.

88 However, with HBOC-201, pressor and fluid requirements were reduced by

89 ed high-risk human livers were perfused with HBOC-based perfusion fluid and matched to 5 RBC-perfused

90 hospital phase," pigs were resuscitated with HBOC-201 (HBOC) or Hextend (HEX) or were nonresuscitated

91 ovascular and metabolic effects of SAAP with HBOC-201 in an exsanguination model of cardiac arrest.

92 nterstitial pulmonary edema was similar with HBOC and HEX, but Po2 was higher with HBOC in severe unc

93 To deter athletes from blood doping with HBOCs such as Hemopure and Oxyglobin (OXY), a method for